company background image
0QAJ logo

DBV Technologies LSE:0QAJ Stock Report

Last Price

€1.50

Market Cap

€204.5m

7D

-7.5%

1Y

27.3%

Updated

02 Jun, 2025

Data

Company Financials +

0QAJ Stock Overview

A clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. More details

0QAJ fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

DBV Technologies S.A. Competitors

Price History & Performance

Summary of share price highs, lows and changes for DBV Technologies
Historical stock prices
Current Share Price€1.50
52 Week High€2.37
52 Week Low€0.51
Beta0.24
1 Month Change-0.73%
3 Month Change108.03%
1 Year Change27.29%
3 Year Change-48.85%
5 Year Change-85.79%
Change since IPO-86.22%

Recent News & Updates

Recent updates

Shareholder Returns

0QAJGB BiotechsGB Market
7D-7.5%1.7%0.6%
1Y27.3%-15.0%3.5%

Return vs Industry: 0QAJ exceeded the UK Biotechs industry which returned -12.9% over the past year.

Return vs Market: 0QAJ exceeded the UK Market which returned 3.4% over the past year.

Price Volatility

Is 0QAJ's price volatile compared to industry and market?
0QAJ volatility
0QAJ Average Weekly Movement17.0%
Biotechs Industry Average Movement9.1%
Market Average Movement5.9%
10% most volatile stocks in GB Market11.5%
10% least volatile stocks in GB Market3.3%

Stable Share Price: 0QAJ's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: 0QAJ's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

FoundedEmployeesCEOWebsite
2002106Daniel Tasséwww.dbv-technologies.com

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. The company’s product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. Its earlier stage research programs include vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes.

DBV Technologies S.A. Fundamentals Summary

How do DBV Technologies's earnings and revenue compare to its market cap?
0QAJ fundamental statistics
Market cap€204.53m
Earnings (TTM)-€100.10m
Revenue (TTM)€3.08m
66.4x
P/S Ratio
-2.0x
P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0QAJ income statement (TTM)
RevenueUS$3.50m
Cost of RevenueUS$0
Gross ProfitUS$3.50m
Other ExpensesUS$117.15m
Earnings-US$113.65m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-0.83
Gross Margin100.00%
Net Profit Margin-3,249.99%
Debt/Equity Ratio0%

How did 0QAJ perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/06/02 05:29
End of Day Share Price 2025/05/30 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

DBV Technologies S.A. is covered by 18 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tazeen AhmadBofA Global Research
Jean-Jacques Le FurBryan Garnier & Co
Liisa BaykoCitizens JMP Securities, LLC